Asset Details
Do you wish to reserve the book?
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment
Do you wish to request the book?
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment
2005
Overview
Cancer-related anemia is a cytokine-mediated disorder resulting from complex interactions between tumor cells and the immune system. Overexpression of certain inflammatory cytokines results in shortened survival of red blood cells, suppression of erythroid progenitor cells, impaired iron utilization, and inadequate erythropoietin production. Numerous other factors may also contribute to the development of anemia in cancer patients. The European Cancer Anaemia Survey (ECAS) has provided the most current, comprehensive, prospectively collected data on the incidence and prevalence of anemia among cancer patients, as well as important perspectives on anemia treatment and relationship of hemoglobin and performance status. ECAS enrolled over 15,000 treated and untreated patients with various malignancies from cancer centers in 24 European countries and followed them for up to 6 months. The initial analysis of the ECAS data revealed that 39% of the total cancer patient population was anemic (hemoglobin <12.0 g/dl) at enrollment, although the rate varied according to tumor type, disease status, and cancer treatment status. Of the patients who were not anemic at enrollment and started cancer treatment during the survey, those undergoing chemotherapy – either alone or in combination with radiotherapy – had the highest incidence of anemia (63 and 42%, respectively). Low hemoglobin levels correlated with poor performance status and only 40% of patients who were anemic at some time during the survey received treatment for their anemia. These findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients’ quality of life and may also improve the clinical outcome.
Publisher
S. Karger AG
Subject
/ Anemia, Hypochromic - diagnosis
/ Anemia, Hypochromic - drug therapy
/ Anemia, Hypochromic - epidemiology
/ Anemia, Hypochromic - etiology
/ Anemia, Hypochromic - physiopathology
/ Anemia, Hypochromic - prevention & control
/ Cancer
/ Chemotherapy, Adjuvant - adverse effects
/ Erythropoietin - therapeutic use
/ Hematinics - therapeutic use
/ Humans
/ MEDICIN
/ MEDICINE
/ Oncology
ISBN
3805579128, 9783805579124
We currently cannot retrieve any items related to this title. Kindly check back at a later time.